The extent of immunological privilege of orthotopic corneal grafts in the inbred rat

Effect of Histocompatibility Y Antigen Matching on Graft Survival in Primary Penetrating Keratoplasty

PURPOSE

To investigate the influence of histocompatibility Y (H-Y) antigen matching on corneal graft survival in primary penetrating keratoplasty (PK).

METHODS

Medical records of patients who underwent primary PK at Seoul National University Bundang Hospital between June 2005 and October 2015 were retrospectively analyzed. The eyes were classified into 2 groups: H-Y-compatible (115 eyes) and H-Y-incompatible (23 eyes). The H-Y-compatible group included donor/recipient combinations of male/male (57 eyes), female/male (44 eyes), and female/female (14 eyes). The H-Y-incompatible group included the male/female (23 eyes) combination alone. A subgroup analysis of low- and high-risk patients according to preoperative diagnoses was also performed. Survival analysis was conducted using the Kaplan-Meier method; differences between groups were assessed with a log-rank test.

RESULTS

A total of 138 eyes from 136 patients (age: 58 ± 18 years) were enrolled. Rejection-free graft survival and graft survival were not significantly different between H-Y-compatible and H-Y-incompatible groups (χ = 0.4, P = 0.548; χ = 1.9; P = 0.17, respectively). Preoperative diagnoses of high-risk cases included those with corneal perforation or thinning (8.7%) and infectious keratitis (7.2%). Low-risk cases included corneal opacity (50.0%), bullous keratopathy (25.4%), keratoconus (5.8%), and corneal dystrophy (2.9%). In the high-risk group, rejection-free graft survival rate was significantly higher in the H-Y-compatible group (χ = 3.9, P = 0.049).

CONCLUSIONS

H-Y antigen matching does not influence graft rejection and failure in cases of primary PK. However, matching the H-Y antigen could help reduce graft rejection, especially in preoperatively high-risk patients.

The Influence of Donor and Recipient Gender Incompatibility on Corneal Transplant Rejection and Failure

In vascularized organ transplants, gender mismatches have higher rates of immunological rejection. We investigated the influence of gender incompatibility, including H-Y incompatibility, on corneal transplant graft rejection and failure. Patients were included who had undergone a first corneal transplant for keratoconus (KC), Fuchs endothelial dystrophy (FED), pseudophakic bullous keratopathy (PBK), infection and other indications. A Cox regression model was fitted for each indication to determine factors affecting graft failure and rejection at 5 years. The impact of gender, including H-Y, matching was analyzed after accounting for other factors, including known risk factors. Of 18 171 patients, 4314 had undergone a transplant for FED, 4783 for KC, 3669 for PBK, 1903 for infection and 3502 for other disorders. H-Y mismatched (male [M]→female [F]) corneas were at greater risk of graft failure or rejection. For FED, F→F were 40% less likely to fail (p < 0.0001) and 30% less likely to reject (p = 0.01); M→M were 20% less likely to fail (p = 0.04) and 30% less likely to reject (p = 0.01). For KC, M→M matched corneas were 30% less likely to fail (p = 0.05) and 20% less likely to reject (p = 0.01) compared with H-Y mismatches. H-Y antigen mismatched (M→F) patients were at greater risk of rejection or graft failure.

The immunobiology of corneal transplantation

Corneal allotransplantation is highly successful in the short term, but much less successful in the longer term. Many corneal grafts in recipients with corneal neovascularization or the sequelae of ocular inflammation undergo irreversible rejection, despite topical immunosuppression with glucocorticosteroids. Sensitization to cornea-derived alloantigen proceeds by both direct and indirect routes, but the anatomic location of sensitization remains unclear. Multiple and redundant mechanisms operate in the effector phase of corneal graft rejection, which is largely cell-mediated rather than antibody-mediated. Human leukocyte antigen matching may improve outcomes in high-risk patients but systemic immunosuppression is frequently ineffective and is seldom used.

Survival and integration of tissue-engineered corneal stroma in a model of corneal ulcer

Tissue-engineered replacement of diseased or damaged tissue has become a reality for some types of tissue, such as skin and cartilage. Tissue-engineered corneal stroma represents a promising concept to overcome the limitations of cornea replacement with allograft. In this study, porcine cornea was decellularized by a series of extraction methods, and the in vivo biocompatibility of the scaffold was measured subcutaneously in rabbits (n = 8). These were not acutely rejected and no abscesses were observed by hematoxylin and eosin staining at the 8th week, indicating that the scaffolds had good biocompatibility. To investigate the potential value of clinical applications, rabbit stromal keratocytes were implanted onto decellularized scaffolds to fabricate tissue-engineered corneal stroma. Allograft, tissue-engineered corneal stroma, or scaffolds were implanted into a model of corneal ulcer. The survival and reconstruction of corneal transplantation were morphologically evaluated by light and electron microscopy until the 32nd week after implantation. Experiments involving transplantation indicated that the epithelial and stromal defect healed quickly, with improvement in corneal clarity. The integration of the graft was accompanied by neurite ingrowth from the host tissue. By 16 weeks after transplantation, the cornea had gradually regained an intact state similar to that of normal cornea. Our results demonstrate that the tissue-engineered corneal stroma with allogenetic cells is a promising therapeutic method for corneal injury.

Matching of the minor histocompatibility antigen HLA-A1/H-Y may improve prognosis in corneal transplantation

BACKGROUND

Minor histocompatibility (H) antigens are peptides of allelic intracellular proteins that play an important role in human leukocyte antigen (HLA) matched transplantations. In an animal model of keratoplasty, minor H antigens have even been reported to exceed the immunogenicity of major H antigens (MHC). This investigation is to assess any benefit of matching the broadly expressed gender (H-Y) and HA-3 antigens in HLA-A1 donor positive human keratoplasty.

METHODS

A total of 229 HLA-A1 donor positive keratoplasties were analyzed. A Cox proportional hazards model and Kaplan-Meier analysis were applied to estimate the effect of H-Y or HA-3 mismatches on rejection-free graft survival.

RESULTS

Eighty-one cases were mismatched for H-Y (male donor to female recipient). A mean follow up of two years showed graft survival as high as 88% in the H-Y compatible group compared to only 77% in the H-Y mismatched group (P = 0.02). Eight out of 62 cases were mismatched for HA-3. No statistically significant influence of HA-3 matching on rejection-free graft survival was observed (85% vs. 73%, P=0.52).

CONCLUSION

HLA-A1/H-Y matching and matching for other broadly expressed minor H antigens may further improve prognosis in keratoplasty.

Mechanisms of Corneal Allograft Rejection

More effective therapies are required to improve clinical corneal allograft outcomes. The strategies that have led to improvements in vascularized organ graft survival are not always applicable to the cornea. New treatments that modulate the afferent arm of the immune response to a corneal allograft are more likely to prove effective than are treatments that target the effector arm of the immune response. We briefly discuss two such options: the use of engineered antibody fragments to block antigen presentation, and the use of gene therapy approaches to abrogate antigen presenting-cell function.

Quantitative evaluation of the corneal endothelium in the mouse after grafting

BACKGROUND/AIM

Corneal graft survival depends critically on the quality of the endothelium. In this study the authors aimed to evaluate corneal endothelium in mice at different times after transplantation and to correlate endothelial integrity with corneal graft survival.

METHODS

Syngeneic and allogeneic corneal grafts at various times (days 0-60) after engraftment were examined in flat mount preparation by confocal microscopy, by evaluating the hexagonal pattern of the endothelial monolayer using actin staining of the cell cortex. Corneas from untreated mice and from mice, who were grafted after removal of draining lymph nodes served as controls.

RESULTS

In control corneas, more than 90% of the posterior surface was covered by endothelium. Syngeneic grafts were always covered by 54-99% of endothelium. In contrast, the posterior surface of corneal allografts showed great variation in the degree of endothelial cell coverage (0-98%). In addition, clinical opacity grading measure was not a reliable predictor of endothelial coverage.

CONCLUSION

In corneal allografts there is progressive loss of endothelium over time, unlike with syngeneic grafts. However, in the early stages of allograft rejection, the grade of graft opacity does not accurately reflect the degree of endothelial cell coverage. Although corneal opacity grade is considered the main determinant of graft rejection, the data suggest that both the grade of corneal opacity plus a sufficient post-graft time duration (>8 weeks in the mouse) are required for the diagnosis of irreversible graft rejection.

Management of high-risk corneal grafts

Corneal transplantation is not invariably successful despite the anterior chamber of the eye being an immunologically privileged site. Inflammation erodes privilege. Other than by reducing inflammation through meticulous surgery, careful postoperative surveillance, and effective topical corticosteroids in the postoperative phase, there is little that a surgeon can do to improve the outlook for the majority of patients receiving corneal transplants. For patients at appreciable risk, HLA Class I matching may help where it is available. So too will systemic immunosuppression where it can be justified. Despite these measures, the results of corneal transplantation have not shown the improvement seen in solid organ transplantation over the last 30 years. New approaches applicable to corneal transplantation are required.

Evaluation of corneal graft rejection in a mouse model

Corneal graft rejection presents clinically and in experimental models as opacification and is considered to be the result of endothelial cell dysfunction or loss. However, recovery from opacification can occur suggesting either (a) that new endothelial cells can regenerate if the original cells were lost, or (b) that sufficient numbers of original cells can regain function if the opacification was due to temporary dysfunction. In this perspective, previous experimental studies of allograft rejection plus some new data are reviewed to support the latter mechanism.

Transplantation immunity and tolerance in the eye: rejection and acceptance of orthotopic corneal allografts in mice

The eye has been considered for a long time as a privileged site, where the normal immune response is not manifested. Using a model of orthotopic corneal allografts in mice we demonstrate that both transplantation immunity and tolerance are expressed in the eye. In two strain combinations, one having genetic disparities at the major histocompatibility complex (MHC) and non-MHC antigens and the other with antigenic differences only in non-MHC antigens, survival of corneal allografts was evaluated in normal unmodified recipients, in recipients presensitized with a skin allograft, and in mice made specifically tolerant to the donor alloantigens. While the corneal allografts in unmodified recipients underwent rejection leading to graft failure in 40-50% of the recipients, all corneal allografts in presensitized recipients were rejected. On the contrary, corneal allografts performed in neonatally tolerant recipients enjoyed survival comparable to that of syngeneic grafts. No significant differences in corneal allograft survival were found between MHC antigen compatible and MHC antigen incompatible strain combinations. The results demonstrate that transplantation immunity and tolerance are efficiently expressed in the eye. Consequently, the local regulatory mechanisms must be responsible for the characteristics of immunity after intraocular immunization and for a high degree of acceptance of corneal allografts in normal recipients.

The mechanisms of corneal graft failure in the rat

The success rate of corneal transplantation is very similar to that of other organ transplantations because corneal transplants can induce an allograft rejection similar to other organ transplants. Only the centre of the cornea can be considered an immunologically privileged site. The reasons for this are considered in this review of experimental corneal grafting which has led to an understanding the immunological mechanisms behind corneal graft rejection. The topics discussed include the role of antigen presenting cells (APCs) in experimental corneal graft rejection and their distribution in the cornea.

Non-MHC antigens and their relative resistance to immunosuppression after corneal transplantation

We have used a high responder rat model to examine the role that non-MHC antigens play in corneal graft rejection. Recipients were backcross animals derived from a cross between two inbred strains, which mimicked the human outbred population in that donor and recipient could be matched or mismatched for MHC antigens, while non-MHC mismatches were variable and unknown. All mismatched grafts and 87% of matched grafts were rejected (median survival 11 and 17 days respectively). The high incidence of rejection of matched grafts indicates that several independently segregating non-MHC genes play a role in rejection. Moreover, the immune response to matched grafts appeared resistant to immunosuppression, suggesting that matching does not permit reduced dosage of immunosuppressants. A mechanism is discussed whereby matching at the class II locus may enhance presentation of mismatched histocompatibility antigens or viral peptides derived from infected graft cells, thereby prejudicing graft survival.

Doyne Lecture. Influences on the development of corneal transplantation

The current status of corneal transplantation is determined by historical events and current research findings. Many of the important historical events occurred in and around Oxford: the beginning of visual science, corneal transplantation and transplantation in immunology. Contemporary research yields data from a number of different sources: clinical trials, registries, surveys, animal experiments and in vitro studies. This information has been used by clinicians to bring about a steady improvement in the outcome of corneal transplantation.

Corneal transplantation--immunologically privileged status

Despite the relatively high success rate and the word 'immunologically privileged site', it has been known that a corneal graft can induce an allograft rejection reaction. This is especially true in the rat where orthotopic penetrating corneal grafts in certain strain combinations are rejected even when transplanted in avascular bed. Reliable microsurgical techniques, together with the availability of inbred or congenic strains and a rapidly developing knowledge of its major histocompatibility complex (MHC) and immune system in general, have made the rat a prime species in which to study the immunological events after corneal grafting. This review describes recent progress in understanding the immunological mechanisms behind corneal graft rejection. The topics discussed include the rat MHC (RT1) antigens and their distribution in the cornea; different responder status in fully allogeneic strain combinations, including the importance of multiple non-MHC antigens; and the role of antigen-presenting cells (APCs) in corneal graft rejection.

Expression of MHC class I and II molecules by cadaver retinal pigment epithelium cells: optimization of post-mortem HLA typing

The objective of this study was to investigate the expression of MHC antigens by retinal pigment epithelium cells (RPE) after stimulation with interferon-gamma (IFN-gamma) and to improve the currently practised technique of cadaver HLA typing. A concentration of 100 U/ml IFN-gamma induced expression of class I molecules up to greater than 90% 3 days after stimulation, whereas 50 U/ml were required for the expression of HLA-DR to greater than 90%. A concentration of 750 U/ml induced 35-45% expression of HLA-DP and less than 25% HLA-DQ after 3 days. Cells were serologically typed using the standard lymphocytotoxicity assay 3 days after stimulation with 250 U/ml IFN-gamma. Typing of class I specificities was complemented by one-dimensional isoelectric focusing (1D-IEF). We observed high concordance between the results of the RPE typing and the lymphocytotoxicity test on the same donors. Our results show complete typing of class I and II antigens post-mortem, which, in particular, enables graft matching and improvement of graft survival in recipients of organs removed many hours after death such as the cornea.

Association between corneal allograft reactions and HLA compatibility

The purpose of this follow-up study is to measure the association between corneal allograft reactions and donor-recipient HLA-A and HLA-B compatibility. Four hundred thirty-eight consecutive adult recipients of corneal grafts with known donor-recipient HLA matching were observed for allograft reactions and failures. Most of the recipients under observation (91%) were well matched for HLA-DR. Of 438 recipients, 158 (36%) completed a 3-year follow-up. Three factors were associated with endothelial allograft reactions: 2 to 4+ corneal vascularization (relative risk, 2.2; P = 0.0006), two mismatched antigens at either the HLA-A or HLA-B locus (relative risk, 2.1; P = 0.0009), and recipient wound size of 8 mm or greater (relative risk, 1.5; P = 0.05). Unexpectedly, a strong association between endothelial allograft reactions and HLA-A or HLA-B incompatibility was found in low-risk recipients defined as unvascularized recipients of a small graft (relative risk, 3.2; P = 0.004). A larger sample size is required to determine if HLA matching offers a solution for recipients with corneal vascularization.